Drugs · Entity Annotation Prototype (beta)

4articles mentioning drugs

23drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: RP1 ×

RP1

This drug is selected. Its supporting articles are shown below.

RP14

Articles mentioning RP1

4 articles · page 1 of 1

600 Retreatment with RP1 in combination with nivolumab in patients with advanced anti-PD-1-failed melanoma

jitc · abstract · 2025-11-04 · 11 matching annotations

94.3%

nivolumab nivo RP1 nivo-related

…notherapy. The IGNYTE trial showed that RP1 in combination with nivolumab (nivo) demonstrated clinically meaningful, durable responses (o…

1327 Biomarker and updated clinical data for RP1 plus nivolumab in anti-PD-1-failed melanoma from the IGNYTE trial demonstrate reversal of mechanisms of resistance to immune checkpoint blockade

jitc · abstract · 2025-11-07 · 7 matching annotations

95.6%

RP1 nivolumab ipilimumab pembrolizumab melanoma

…unother Cancer. 2019;7:214.Wong MK, Milhem MM, Sacco JJ, et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (…

611 RP1 plus nivolumab in patients with and without prior BRAF-directed therapy: a subgroup analysis of patients with anti-PD-1-failed BRAF-mutant melanoma from the IGNYTE clinical trial

jitc · abstract · 2025-11-04 · 4 matching annotations

93.1%

nivolumab RP1 Vusolimogene oderparepvec BRAFi melanoma anti-PD-1 therapy

…vec (RP1; an HSV-1-based oncolytic immunotherapy) combined with nivolumab demonstrated clinically meaningful, durable antitumor activity …

Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling

jitc · abstract · 2026-03-03 · 1 matching annotations

75.2%

vusolimogene oderparepvec RP1 tumor

…s (splenocytes) were cultured separately, or in co-culture with vusolimogene oderparepvec, an oncolytic herpes simplex virus expressing the fusogenic gib…